• β-Aminobutyric acid (GABA) agonists have been proposed for the treatment of tardive dyskinesia, but their therapeutic potential has been limited by side effects and toxicity. To elucidate further the role of GABA in neuroleptic-induced dyskinesias, we evaluated tetrahydroisoxazolopyridinol (THIP), a new, less toxic GABA analog and GABA receptor agonist, in both a dose-finding (single-dose) pilot study with five patients and a longer (four-week) placebo-controlled study with 13 patients. The patients were videotaped during a standardized examination; tardive dyskinesia, parkinsonian symptoms, and eye-blinking rates were rated blindly and randomly. The maximal shortterm dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. Psychiatric symptoms showed no significant changes, although tension and depression lessened. Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks. Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome.
Korsgaard S, Casey DE, Gerlach J, Hetmar O, Kaldan B, Mikkelsen LB. The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist. Arch Gen Psychiatry. 1982;39(9):1017–1021. doi:10.1001/archpsyc.1982.04290090021005
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.